CVS Health (NYSE:CVS) Updates FY 2025 Earnings Guidance

CVS Health (NYSE:CVS) issued an update on its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.600-6.700 for the period, compared to the consensus EPS estimate of 6.610. The company issued revenue guidance of $400.0 billion-$400.0 billion, compared to the consensus revenue estimate of $399.0 billion.

CVS Health Trading Down 0.1%

Shares of CVS stock opened at $77.70 on Friday. The company has a market capitalization of $98.63 billion, a P/E ratio of 204.47, a P/E/G ratio of 0.77 and a beta of 0.48. CVS Health has a 12-month low of $43.56 and a 12-month high of $85.15. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. The firm has a 50-day moving average price of $79.09 and a 200 day moving average price of $72.37.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.24. The firm had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Research analysts forecast that CVS Health will post 5.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on CVS shares. The Goldman Sachs Group boosted their price objective on CVS Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. UBS Group restated an “outperform” rating on shares of CVS Health in a research report on Wednesday, December 10th. Wells Fargo & Company reduced their target price on shares of CVS Health from $103.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 13th. Zacks Research lowered shares of CVS Health from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Finally, TD Cowen lifted their target price on CVS Health from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $94.67.

Institutional Investors Weigh In On CVS Health

A number of hedge funds have recently modified their holdings of the business. MUFG Securities EMEA plc bought a new stake in shares of CVS Health during the second quarter worth $258,000. Financial Advisors Network Inc. increased its holdings in CVS Health by 12.9% during the 2nd quarter. Financial Advisors Network Inc. now owns 3,699 shares of the pharmacy operator’s stock worth $255,000 after purchasing an additional 423 shares in the last quarter. Legacy Advisors LLC acquired a new stake in shares of CVS Health in the 3rd quarter valued at about $249,000. Modern Wealth Management LLC lifted its holdings in shares of CVS Health by 17.8% in the second quarter. Modern Wealth Management LLC now owns 3,542 shares of the pharmacy operator’s stock valued at $244,000 after purchasing an additional 535 shares in the last quarter. Finally, McIlrath & Eck LLC boosted its position in shares of CVS Health by 422.9% during the second quarter. McIlrath & Eck LLC now owns 3,383 shares of the pharmacy operator’s stock worth $233,000 after buying an additional 2,736 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.